Combinatorial Inhibition of Complement Factor D and BCL2 for Early-Onset Colorectal Cancer.

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• The tumor immune microenvironment differs between early-onset and late-onset colorectal cancer, influencing tumor progression.
• Specific genes, including complement factor D, show increased expression in early-onset colorectal cancer patients.

Purpose of the Study:

• To validate differential immune gene expression in early-onset versus late-onset colorectal cancer.
• To evaluate targeted drug efficacy on genes upregulated in early-onset colorectal cancer using preclinical models.

Main Methods:

• Retrospective cohort study analyzing tumor RNA from formalin-fixed paraffin-embedded samples.
• Immunohistochemistry for gene expression and function validation.
• In vivo preclinical tumor studies in mouse models treated with complement factor D and BCL2 inhibitors.

Main Results:

• Complement factor D and BCL2 were confirmed as elevated in early-onset colorectal cancer.
• Combined inhibition of complement factor D (danicopan) and BCL2 (venetoclax) reduced tumor burden in a mouse model.
• The drug combination induced observable toxicity in the preclinical model.

Conclusions:

• Combined inhibition of early-onset associated genes complement factor D and BCL2 demonstrates potential in slowing colorectal cancer growth.
• The study highlights a potential therapeutic approach for early-onset colorectal cancer, acknowledging limitations in sample size and model system.
• Further research is warranted to optimize this combinatorial therapy and mitigate toxicity.